Atlas Trials

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Clinical trial NCT02374333 · COMPLETED

Trial details

NCT number
NCT02374333
Sponsor
University of Pennsylvania
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Lymphocytic LeukemiaDiffuse Large Cell Lymphoma
Start date
2014-03-25
Primary completion
2021-09-02
Enrollment
81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.